Pfizer's axitinib improves PFS vs. Nexavar from Bayer/Onyx in RCC
One byproduct of recent development successes in metastatic renal cell carcinoma has been the emergence of questions about how best to use the various drugs. A variety of head-to-head studies are underway, and the first direct comparison of targeted agents was provided last month by Pfizer Inc., which reported axitinib met the primary endpoint of a Phase III trial, significantly improved progression-free survival vs. Nexavar sorafenib in second-line RCC.
Pfizer did not disclose detailed data on the pan-VEGF receptor tyrosine kinase inhibitor (TKI) because it plans to present the results at a scientific meeting in 1H11.
Glen Andrews, an asset team leader in Pfizer's oncology business unit, told